Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
(... Continued)<br />
Study or subgroup DHA-P Control Risk Ratio Weight Risk Ratio<br />
Heterogeneity: not applicable<br />
Test <strong>for</strong> overall effect: Z = 0.76 (P = 0.45)<br />
5 Day 28: DHA-P vs Amodiaquine plus sulfadoxine-pyrimethamine<br />
n/N n/N M-H,Random,95% CI M-H,Random,95% CI<br />
Karema 2004 RWA 10/236 38/227 63.8 % 0.25 [ 0.13, 0.50 ]<br />
Zongo 2007 BFA 4/172 7/167 36.2 % 0.55 [ 0.17, 1.86 ]<br />
Subtotal (95% CI) 408 394 100.0 % 0.32 [ 0.16, 0.64 ]<br />
Total events: 14 (DHA-P), 45 (Control)<br />
Heterogeneity: Tau 2 = 0.06; Chi 2 = 1.24, df = 1 (P = 0.27); I 2 =19%<br />
Test <strong>for</strong> overall effect: Z = 3.23 (P = 0.0012)<br />
0.005 0.1 1 10 200<br />
Favours DHA-P Favours Control<br />
Analysis 19.1. Comparison 19 How does Artesunate plus mefloquine per<strong>for</strong>m?, Outcome 1 Effectiveness:<br />
Total Failure (P. falciparum) PCR adjusted.<br />
Review: <strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria<br />
Comparison: 19 How does Artesunate plus mefloquine per<strong>for</strong>m?<br />
Outcome: 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted<br />
Study or subgroup ASMQ Control Risk Ratio Risk Ratio<br />
1 Day 63: AS+MQ vs Dihydroartemisinin-piperaquine<br />
n/N n/N M-H,Random,95% CI M-H,Random,95% CI<br />
Ashley 2003b THA 9/131 3/131 3.00 [ 0.83, 10.83 ]<br />
Janssens 2003 KHM 5/190 4/181 1.19 [ 0.32, 4.36 ]<br />
Ashley 2004 THA 7/137 3/292 4.97 [ 1.31, 18.94 ]<br />
Grande 2005 PER 0/224 4/211 0.10 [ 0.01, 1.93 ]<br />
Subtotal (95% CI) 682 815 1.77 [ 0.55, 5.72 ]<br />
Total events: 21 (ASMQ), 14 (Control)<br />
Heterogeneity: Tau 2 = 0.78; Chi 2 = 6.94, df = 3 (P = 0.07); I 2 =57%<br />
Test <strong>for</strong> overall effect: Z = 0.95 (P = 0.34)<br />
2 Day 42: AS+MQ vs Artemether-lumefantrine<br />
Hutagalung 2002 THA 9/212 3/201 2.84 [ 0.78, 10.36 ]<br />
Van den Broek 2003a BGD 0/105 3/102 0.14 [ 0.01, 2.65 ]<br />
Stohrer 2003 LAO 0/45 3/37 0.12 [ 0.01, 2.21 ]<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
0.005 0.1 1 10 200<br />
Favours ASMQ Favours Control<br />
(Continued ...)<br />
211